We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+13.82%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.16B
AUM Growth
+$298M
Cap. Flow
+$233M
Cap. Flow %
19.99%
Top 10 Hldgs %
67.73%
Holding
38
New
15
Increased
4
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$64.7M
2
IMMU
Immunomedics Inc
IMMU
+$37.1M
3
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$31.3M
4
FOLD
Amicus Therapeutics
FOLD
+$29.5M
5
ARGX icon
argenx
ARGX
+$25.4M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$47.3M
2
QURE icon
uniQure
QURE
+$21.3M
3
ALLK
Allakos
ALLK
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$177M 15.19%
1,715,560
– –
ODT
2
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$123M 10.61%
3,363,377
+384,615
+13% +$9.22M
ONC
3
BeOne Medicines Ltd
ONC
$32.8B
$112M 9.59%
900,000
– –
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$91.1M 7.83%
6,567,000
+2,467,000
+60% +$37.1M
ONCE
5
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$61.4M 5.28%
+600,000
New +$64.7M
QURE icon
6
uniQure
QURE
$3.03B
$48.1M 4.13%
615,400
-334,600
-35% -$21.3M
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
$45.4M 3.9%
975,000
– –
PTCT icon
8
PTC Therapeutics
PTCT
$5.64B
$45M 3.87%
1,000,000
– –
DBVT
9
DBV Technologies
DBVT
$799M
$43.6M 3.75%
530,000
+110,000
+26% +$9.83M
GOSS icon
10
Gossamer Bio
GOSS
$82.9M
$41.6M 3.58%
1,875,000
– –
BCEL
11
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$32.7M 2.81%
+1,733,583
New +$31.3M
MIST icon
12
Milestone Pharmaceuticals
MIST
$138M
$29.9M 2.57%
+1,102,194
New +$22.7M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$29M 2.49%
+2,325,000
New +$29.5M
ARGX icon
14
argenx
ARGX
$53.4B
$28.3M 2.43%
+200,000
New +$25.4M
MDCO
15
DELISTED
Medicines Co
MDCO
$27.4M 2.35%
750,000
+150,000
+25% +$4.9M
WVE icon
16
Wave Life Sciences
WVE
$1.09B
$26.1M 2.24%
1,000,000
– –
RCKT icon
17
Rocket Pharmaceuticals
RCKT
$340M
$22M 1.89%
1,466,051
– –
ALLK
18
DELISTED
Allakos
ALLK
$20.6M 1.77%
475,000
-324,000
-41% -$13.3M
SLDB icon
19
Solid Biosciences
SLDB
$794M
$20M 1.72%
231,551
– –
KURA icon
20
Kura Oncology
KURA
$800M
$16.6M 1.43%
844,789
– –
PRVL
21
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$14.8M 1.27%
+1,123,105
New +$16.4M
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.2M 1.13%
250,000
– –
ESPR
23
CALL
DELISTED
Esperion Therapeutics
ESPR
$11.6M 1%
+250,000
New +$11.7M
CBAY
24
DELISTED
Cymabay Therapeutics
CBAY
$8.95M 0.77%
1,250,000
– –
MTNB icon
25
Matinas BioPharma
MTNB
$1.88M
$8.73M 0.75%
203,766
– –
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Boxer Capital held 38 positions worth $1.16B, up 35% from $865M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Boxer Capital deployed $233M of net new capital in Q2 2019, opening 15 new positions and adding to 4 existing holdings. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 600,000 shares worth $61.4M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $21.3M trimmed.

  • Boxer Capital's largest Q2 2019 buy was Spark Therapeutics, Inc. Common Stock: 600,000 shares worth $61.4M.
  • Boxer Capital added most to Immunomedics Inc in Q2 2019, an estimated $37.1M increase.
  • Boxer Capital's biggest Q2 2019 reduction was uniQure, cutting an estimated $21.3M.
  • Boxer Capital fully exited Biogen in Q2 2019, selling an estimated $47.3M.
  • Boxer Capital's ten largest holdings make up 68% of its $1.16B portfolio in Q2 2019.
  • Boxer Capital opened 15 new positions and closed 1 in Q2 2019.
  • Boxer Capital's portfolio value rose 35% quarter-over-quarter to $1.16B.

Based on Boxer Capital's 13F filing for Q2 2019, filed 14 Aug 2019.